NRDL+ China Access Mid-Year Strategic Debrief: Share Your Perspective

Thank you for taking about 5 minutes to share your perspective.

The upcoming NRDL+ China Access Mid-Year Strategic Debrief is scheduled for publication in August 2026. As part of the development process, we are gathering input from leaders across the life sciences industry to better understand the questions, decisions, and information needs that matter most as China's access environment continues to evolve.

We’ll share a complimentary Executive Summary with everyone who shares their thoughts when the debrief is published.

The full Mid-Year Strategic Debrief will be available as an on-demand executive briefing through NRDL+ Access360 membership or as a standalone purchase. 



About NRDL+

NRDL+ is a strategic intelligence platform focused on China’s evolving health policy, coverage, and financing system for medical technologies. Through the Access360 membership program, NRDL+ Masterclass, and its mid-year and annual China Access Outlook Strategic Debriefs, NRDL+ helps life sciences leaders track policy signals, interpret implementation dynamics, and connect China’s access environment to pricing, reimbursement, portfolio, commercialization, and long-range forecasting decisions. NRDL+ is powered by bizi LLC, a New Jersey–based consultancy founded by Kelly Ke, a former senior advisor in Deloitte US’s Life Sciences practice. Kelly’s co-authored analysis on China’s C-List and multi-layer coverage framework has been published in Caixin and republished in China Reform magazine.